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The aim of this study was to establish a method that could differentiate antibodies against live and
inactivated vaccines of porcine reproductive and respiratory syndrome virus (PRRSV). A blocking ELISA
(b-ELISA) was established using the PRRSV non-structural protein, Nsp9, as the antigen and a monoclonal
antibody, 2D6, against the Nsp9 protein as the capture antibody. The test was validated by using 415
clinical sera in the b-ELISA compared to a commercial kit based on the indirect ELISA using the
nucleocapsid (N) protein as antigen. Signiﬁcant differences were observed for the data obtained by the
two detection methods. This may be due to the commercial kit detecting antibodies elicited by live and
inactivated virus, whereas the b-ELISA only detects antibodies produced by any active viral replication,
such as natural infection or live vaccination. Therefore, the b-ELISA in this study is able to distinguish
between antibodies against live and inactivated viruses in pigs.
& 2013 Elsevier Inc. All rights reserved.Introduction
Porcine reproductive and respiratory syndrome virus (PRRSV)
was ﬁrst discovered in North America in 1987 and in Europe in
1990 (Andreyev et al., 1997; Benﬁeld et al., 1992). Porcine repro-
ductive and respiratory syndrome (PRRS) continues to be a threat
to the swine industry worldwide (Dea et al., 1992; Gao et al., 2004;
Kapur et al., 1996). Higher levels of viremia and virus excretion
were observed in younger versus older pigs, and age-dependent
variation in disease severity was observed in young pigs (Dea et al.,
2000; Feng et al., 2008). The unprecedented large-scale PRRS
outbreaks in 2006 occurred over nearly half of China and
involved42,000,000 pigs, a matter of serious concern to the
global swine industry and to the public health (Tian et al., 2007).
PRRSV is a small, enveloped RNA virus that belongs to the order
Nidovirales, family Arteriviridae, genus Arterivirus, along with
Equine arteritis virus, Lactate dehydrogenase-elevating virus of
mice, and Simian hemorrhagic fever virus (den Boon et al., 1991;
Ziebuhr et al., 2000). The virus genome contains a 5′-cap and 3′-
polyadenylate single-strand positive-sense RNA of approximatelyll rights reserved.
ang),
).15 kb. The viral genomic RNA contains at least nine open reading
frames (ORFs), including ORF1a, ORF1b, ORF2a, ORF2b, ORFs3-7,
and 5′- and 3′-untranslated regions (den Boon et al., 1991). ORF1a
and ORF1b comprise the majority of the 5′-terminal region of the
genome, and encode the replicase polyprotein, which is consid-
ered to be auto-proteolytically cleaved into at least 13 non-
structural proteins (Nsps) assumed to be associated with the viral
replication and transcription (Snijder et al., 1996). Among the non-
structural genes of PRRSV, Nsp9 contained within ORF1b is the
most conserved region of nidovirus genomes and encodes the
RNA-dependent RNA polymerase (RdRP) (Kiss et al., 2006).
Virus isolation, polymerase chain reaction (PCR), virus neutra-
lization, indirect ﬂuorescent antibody assay (IFA), and ELISA have
been used to diagnose PRRSV infection (Ferrin et al., 2004). Each
method has its advantages, but diagnosis of PRRS has traditionally
been based on the detection of antibodies (Abs) and/or the
isolation of virus. An early diagnosis can often be achieved by
the detection of PRRSV genomes by PCR or other nucleic acid tests
(Christopher-Hennings et al., 1995), while Abs are detected late in
the course of disease. At present, serology still remains an
important tool for the diagnosis of PRRS, and for retrospective
epidemiological studies of outbreaks and prevalence. Several ELISA
tests mostly based on the virus nucleocapsid (N) protein are
commercially available to diagnose the disease (Jankova and
Celer, 2012). An indirect ELISA kit, the IDEXX HerdChek PRRS
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Abs against PRRSV because of high sensitivity, speciﬁcity, and
repeatability (Chen et al., 2013; Jankova and Celer, 2012). Although
the kit has the ability to detect Abs against both types of PRRSV, it
cannot distinguish Abs from live and inactivated PRRSV. In the
case, the development and application of speciﬁc, sensitive, and
validated serological methods to solve this problem is still impor-
tant for the control of PRRS.
Infected animals, whether symptomatic or not, usually elicit
Abs to both the PRRSV structural proteins (Sps) and Nsps (Johnson
et al., 2007). Since Nsps are exclusively synthesized during the
PRRSV replication cycle and uninfected animals that had been
vaccinated by inactivated virus preparations only elicit Abs to Sps
(Paton et al., 2006) therefore the presence of anti-Nsp Abs in
animal sera is a clear indication of virus activity.
In this study, the Nsp9 gene of American serotype of PRRSV was
cloned and expressed to produce a novel monoclonal antibody
(mAb). The aim of this study was to establish a sensitive and
speciﬁc b-ELISA using a puriﬁed Nsp9 fusion protein antigen and
the well-characterized 2D6 mAb and to evaluate the serological
diagnostic potential for differentiation of post-infection and post-
vaccination antibodies vaccinated with the inactivated vaccine.Fig. 2. Western blot analysis of recombinant Nsp9 antigen with the positive
porcine antiserum (Lane 1) and 2D6 mAb (Lane 2), respectively. Lane M:
pre-stained protein ladder.Results
Monoclonal antibodies against the Nsp9 protein
An 840 bp fragment representing the cDNA of Nsp9 was
obtained by PCR (data not shown). The apparent molecular weight
of the fusion protein was approximately 34 kDa by SDS-PAGE
(Fig. 1). A mAb was generated that recognized the Nsp9 fusion
protein, named 2D6 (IgG1), which was produced at high titer by
the hybridoma (640,000). The afﬁnity constant for 2D6 was
determined to be 1.8109. The 2D6 mAb can specially recognize
the Nsp9 protein by western blot (Fig. 2). The IFA results showed
that only cytoplasmic ﬂuorescence was observed in PRRSV-
infected MARC-145 cells (Fig. 3). Additionally, 2D6 displayed
speciﬁc detection of PRRS antigens in parafﬁn-embedded tissue
sections from a pig infected by SW/JL/07 (Fig. 4). All these results
suggested that 2D6 is able to detect PRRSV, and is likely to be
suitable for use in a b-ELISA that requires speciﬁc Abs.Fig. 1. Analysis of recombinant PRRSV Nsp9 proteins expressed in Escherichia coli
by SDS-PAGE. Lane 1: E. coli control (parental vector); Lane 2: negative control with
BL21; Lane 3: recombinant PRRSV Nsp9 protein; Lane 4: puriﬁed recombinant
PRRSV Nsp9 protein; M: pre-stained protein ladder.Characterization of Abs against Nsp9 and N proteins during disease
Changes in the Abs levels against Nsp9 and N proteins during
PRRS were detected by the commercial kit and the b-ELISA. In
Fig. 5, inactivated virus did not induce the production of Nsp9 Abs,
but could induce the production of Abs against the N proteins. Live
virus can not only induce structural protein Abs, but also induce
non-structural protein Abs, such as anti-Nsp9. The PI values
recorded from PRRS reference antisera at a 1:5 dilution were
between 31.7 and 72.2% (Fig. 6). All 25 positive sera showed that a
recorded PI of430% conﬁrmed samples to be speciﬁc for PRRSV.
Antisera prepared against ﬁve other related virus (CSFV, PPV, PRV,
PCV, and JEV) displayed inhibition values o15.0%, and were
therefore recorded as negative and deemed to not cross-react
with PRRSV. The sensitivity of the b-ELISA showed that a 1:40
dilution of positive sera was the highest dilution, which showed a
signiﬁcant difference between positive and negative controls
(Po0.05) (Fig. 7).
Comparison of commercial and b-ELISA tests
A comparison of serological reactivity of both ELISA tests was
performed on all groups of swine sera (Table 1). The results of 126
sera from PRRS free herds vaccinated with an inactivated vaccine
conﬁrmed the assumption that inactivated vaccine does not induce
Nsp9 speciﬁc antibodies. For other 289 serum samples, 131 were
determined to be negative by both methods (Tables 1 and 2).
Samples determined to be positive results by the b-ELISA were also
positive by the commercial kit (n¼154), while some of the positive
results detected by the kit were determined to be negative by the b-
ELISA (n¼2). According to the clear immunization history of pig
herbs, it can deduce that the b-ELISA method can differentiate Abs
Fig. 3. Detection of PRRSV in MARC-145 cells three days after inoculation. Immunostaining was performed using the 2D6 mAb for the detection of Nsp9 protein. A, PRRSV-
infected MARC-145 cells; B, negative control. Magniﬁcation: 200 .
Fig. 4. IHC detection of PRRSV antigen in tissue samples from pigs on day 7 following infection with PRRSV SW/JL/07. A, lung; B, negative lung control; C, liver; D, negative
liver control; E, kidney; F, negative kidney control; G, thyroid; H, negative thyroid control. Magniﬁcation: 200 .
Fig. 5. Changes in N (A) and Nsp9 (B) antibodies during PRRSV infection. *, **, and *** denote po0.05, po0.01, and po0.001, respectively.
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%CV was 4.8, the %CV between plates in one run was 3.04, and the %
CV between runs was 3.4. The b-ELISA antibody titers of these sera
based on a 30% end-point were determined to be between 20 and
160. For 415 samples, the sensitivity for Nsp9 protein was calculated
to be 98.7% and 98.5% of speciﬁcity when compared with the
commercial kit (Table 3).Discussion
Along with the harm caused by PRRSV infection and the
extensive application of vaccines, the differential diagnosis of
PRRS is a major aspect of disease detection and control. Currently,
serological diagnostic methods for the diagnosis of PRRS are more
common, but serological methods to distinguish between natural
Fig. 6. The b-ELISA analysis of 25 positive serum samples. Black bars show the
A490 of the b-ELISA. Gray bars show the percentage inhibition of 2D6 produced by
sera. White bar represents the negative control. The data was obtained using PRRSV
Nsp9 as the target antigen. Data means mean7SD. **, *** denote po0.01 and
po0.001, respectively.
Fig. 7. Sensitivity analysis of the b-ELISA. Six twofold serial dilutions of a positive-
control serum and a negative-control serum were tested. A 1:40 dilution of the
positive control was determined as the limit of analytical sensitivity. *, *** denote
po0.05 and po0.001, respectively.
Table 1




in the commercial kita
Antibody positive
in b-ELISA
1 126b 120/126 0/126
2 157c 149/157 147/157
3 54d 7/54 9/54
4 78e 0/78 0/78
Total 415 276/415 156/415
a The commercial kit is based on an indirect ELISA.
b The sera were from the pigs immunized by an inactivated vaccine.
c The sera were from the pigs immunized by a live vaccine.
d The sera were from pigs showing PRRS clinical signs.
e The sera were from the PRRS negative herbs.
Table 2
Comparison of the commercial kit and b-ELISA tests.
Commercial kit
Positive Negative Total
Positive 154 (53.3%) 2 (0.7%) 156 (54.0%)
B-ELISA Negative 2 (0.7%) 131 (45.3%) 133 (46.0%)
Total 156 (54.0%) 133 (46.0%) 289 (100%)
Table 3
Sensitivity and speciﬁcity of the commercial kit and b-ELISA. Sensitivity and
speciﬁcity of the b-ELISA were calculated using the commercial kit as the reference
method of detection for the swine sera (n¼289). Those of the commercial kit were
determined using the b-ELISA as the reference assay. Sensitivity and speciﬁcity
were calculated as follows:.
Test Sensitivity (%) Speciﬁcity (%)
Commercial ELISA 98.7 98.5
B-ELISA 98.7 98.5
Sensitivity¼TP/(TP+FN)100,
Speciﬁcity¼TN/(TN+FP)100,where TP, FN, TN, and FP indicate true-positive,
false-negative, true-negative and false-positive, respectively.
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develop a diagnostic method that is able to distinguish between
the vaccinated and naturally infected animals is important for
disease prevention, diagnosis and treatment. MAbs can not only be
used for the rapid and accurate diagnosis of pathogens but also beused for PRRS epidemiology and treatment of disease. Their
application in diagnostic methods has proven their ability to
detect animals that may not yet display clinical symptoms or
detect a history of the previous exposure.
In the present study, the Nsp9 protein was chosen as the ELISA
antigen because the homology of this region is highly conserved
within PRRSV genomes of all American serotypes and relatively
low compared with those European serotypes. With the 2D6 mAb
speciﬁc to Nsp9, a b-ELISA method was developed because this
method is superior as a screening test compared with the indirect
ELISA: (i) the b-ELISA was better than the indirect ELISA in
detecting Abs formed early after infection and superior to the
indirect ELISA in detecting Abs at a late stage of infection; (ii) the
b-ELISA gave higher Ab-units, while some sera with low Ab levels
in the b-ELISA were negative in the indirect ELISA, indicating that
the b-ELISA had a better ability to detect low levels of Abs; and (iii)
it did not require a control antigen and therefore the double
number of samples could be tested on each plate, compared to the
indirect ELISA, resulting in a higher capacity and a cheaper test
(Sorensen et al., 1997). This assay exhibited high afﬁnity for PRRSV
with no cross-reactivity to common pig pathogens, such as CSFV,
PPV, PRV, PCV, and JEV. To evaluate the sensitivity and speciﬁcity
of the b-ELISA, 289 serum samples were examined. The results
demonstrated similar sensitivity and speciﬁcity values for the b-
ELISA and the commercial kit. As far as we know, this is the ﬁrst
mAb speciﬁc for Nsp9 which can be efﬁciently used to differentiate
infected and vaccinated animals.
Vaccination is one of the most effective tools to control PRRS,
although it does not prevent PRRSV infection. The inactivated
vaccines are safety and generally commended to use for only
healthy pig herds and breeding sows in China, while the live
vaccines have proved much more efﬁcacious. But the vaccine virus
may shed, which is then transmitted in the ﬁeld, complicating the
problem of detecting infection with wild-type virus, both through
virology and serology (Zimmerman et al., 2006). Also, it has a rate
of reversion to virulent strain. Despite the problems mentioned
above, both inactivated and live vaccines against PRRSV have been
developed and are widely used in China. Therefore, the b-ELISA is
more useful for PRRS-negative farms, where pigs are vaccinated
with inactivated PRRSV vaccines and thus differentiation between
post-infection and post-vaccination Abs can provide important
Y. Cong et al. / Virology 444 (2013) 310–316314insight into whether the circulation of ﬁeld virus strains happens
in these herds.
One of the drawbacks of the study was that it is undetermined
whether a positive result by b-ELISA was due to infection with
natural virus or immunization with live vaccines. However, the b-
ELISA will display its advantage for herbs immunized by the
inactivated vaccines. In addition, it is also undetermined whether
this method is able to differentiate Abs against both virus
serotypes because there is no European-type PRRSV strain in our
lab, although a few of European- PRRSVs have been described in
China. In summary, the PRRS b-ELISA was proven to be appropriate
for the diagnosis of PRRSV infections and continues to be an
important tool for PRRS surveillance in pigs.Materials and methods
Ethics statement
All animal research was conducted according to the experi-
mental practices and standards approved by the Animal Welfare
and Research Ethics Committee at Jilin University (Approval ID:
20100926–1).Virus and sera
The American-type PRRSV, SW/JL/07, was isolated by our
laboratory. 25 control positive sera from animals immunized by
a live vaccine were identiﬁed as positive by a commercial kit based
on the indirect ELISA (Lv Shiyuan, China) and 25 control negative
sera were obtained from farms with no history of PRRS infection.
The antisera to classical swine fever virus (CSFV), porcine parvo-
virus (PPV), porcine pseudorabies (PRV), porcine circovirus (PCV),
and Japanese encephalitis virus (JEV) were prepared by our
laboratory.Cloning, expression, and puriﬁcation of PRRSV Nsp9 polypeptide
The coding region for SW/JL/07 Nsp9 (GenBank: KF049009) was
ampliﬁed by PCR from virus-derived cDNA using the forward primer,
5′-TCAAGCTTTGAGTGAGGTTGAGCTAAAAGAC-3′ and reverse primer,
5′-CGCTCGAGTCAGACAGTTTGCCAGTTTTCTCG-3′ that were engi-
neered to contain Hind III and Xho I restriction sites (underlined),
respectively. The Nsp9 PCR product was cloned into the pET-28a (+)
vector, resulting in pET-28-Nsp9, which contained the fragment gene
(coding for nucleotides 7819–8658) with a C-terminal extension,
including a His-tag for protein puriﬁcation. After veriﬁcation by
restriction analysis and nucleotide sequencing, the pET-28-Nsp9 was
used to transform competent E. coli BL21 (DE3). Cultures were grown
in Luria-Bertani medium containing 50 μg/mL kanamycin at 37 1C
until cells reached an absorbance of 0.4 at a wavelength of 660 nm.
Cells were induced with 1 mM isopropyl-β-D-thio-galactoside (IPTG)
and grown for a further 4 h at 37 1C (shaking at 200 rpm). Cells were
then harvested by centrifugation at 5000 g for 20 min at 4 1C and
the resulting cell pellets were frozen at 20 1C. For lysis, the cell
pellets were resuspended in 20 mM Tris–HCl, 300 mM NaCl, 5 mM
dithiothreitol (DTT), and 20 mM imidazole (pH 7.4). Cells were lysed
by French press after the addition of glycerol to 10 v/v% and one
complete EDTA-free protease inhibitor cocktail tablet. The Nsp9
fusion proteinwas puriﬁed by afﬁnity chromatography using HisBind
column according to manufacturer’s instructions (GE, USA). The
purity and concentration of the protein were analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
western blot.Preparation of Nsp9 mAbs
The mAbs against the PRRSV Nsp9 polypeptide were generated
using standard protocols (Kim et al., 2006). Brieﬂy, the Nsp9 fusion
protein was emulsiﬁed (1:1, v/v) with Freund’s complete adjuvant
for primary immunizations and two female BALB/c mice were
injected intraperitoneally with 100 mL of this emulsion. In the
second and third injections, mice were immunized by the same
method with 100 mL of antigen with Freund’s incomplete adjuvant.
Mice received a booster injection of 100 mg of the protein in PBS
before cell fusion. The immune period was at the interval of two
weeks, respectively. Three days after the ﬁnal immunization, mice
were sacriﬁced and spleens were aseptically removed for cell
fusion. Hybridomas were cultured in RPMI-1640 medium contain-
ing 1 v/v% hypoxanthine-aminopterin-thymidine (Sigma, USA) in
96-well ﬂat-bottom culture plates. The fused hybridoma clones
were screened by an indirect ELISA for mAbs that recognized Nsp9
protein. The indirect ELISA protocol was performed as described
previously for PRRSV (Wright et al., 1993): (i) 100 μL PRRSV Nsp9
fusion protein was incubated at a predetermined dilution (1.5 μg/
mL) in coating buffer for overnight at 4 1C; (ii) 5% BSA blocking
buffer for 1 h at 37 1C; (iii) supernatants of the cloned hybridoma
(100 μL/well) were incubated for 1 h at 37 1C; (iv) goat anti-mouse
IgG-HRP (1:5000) (Sigma, USA) in PBST was incubated for 1 h at
37 1C; (v) 100 μL OPD substrate was allowed to react for 20 min at
room temperature before addition of 50 μL of 2 M H2SO4 to stop
the reaction. During the procedure, wells were washed ﬁve times
with washing buffer after each step. Optical density (OD) readings
were obtained at a wavelength of 490 nm.
Positive hybridomas were cloned by limiting dilution for three
rounds, and the supernatants were used for further characteriza-
tion. Ascites were produced by intraperitoneal injection of 5105
hybridoma cells into BALB/c mice that were treated with 0.5 mL/
mouse pristane (Sigma, USA). The subclass speciﬁcity of mAbs was
determined using the IsoStrip mouse monoclonal antibody iso-
typing kit (Sigma, USA). Measurement of the afﬁnity of the mAbs
for Nsp9 was performed as previously described (Karlsson et al.,
1991).Characterization of Nsp9-speciﬁc mAbs
The puriﬁed Nsp9 was subjected to electrophoresis on 12%
SDS-PAGE gels. Western blot was used to analyze the reactivity
between the bacterially-expressed His-tagged Nsp9 protein and
porcine antisera to PRRSV and the prepared mAbs, respectively.
Ten micrograms of the puriﬁed Nsp9 protein was subjected to
SDS-PAGE, and then electrotransferred to polyvinylidene ﬂuoride
(PVDF) membrane (Millipore, USA). After blocking with 5% bovine
serum albumin (BSA) for 1 h at 37 1C, the strips were incubated
with porcine antisera to PRRSV (1:40) or the mAbs (1:20,000 for
the acsite), and detected with rabbit anti-pig IgG-HRP (1:5000)
(Sigma, USA) or goat anti-mouse IgG-HRP (1:5000) (Sigma, USA).
After washing, the reaction was developed using 3,3′-diamino-
benzidine (DAB) substrate (Sigma, USA) on the PVDF membrane
for 1 min for color development.
In order to validate the binding potential of the mAbs with live
virus, MARC-145 cells cultured on glass coverslips were infected with
200 μL of a 104 TCID50 viral suspension of SW/JL/07 and incubated at
37 1C for 72 h in a humidiﬁed 5% CO2 environment. Negative controls
were prepared in an identical manner with cell culture medium
instead of virus. Coverslips were removed and washed twice with
PBST (pH 7.4). Cells were ﬁxed in freshly prepared 3.7% paraformal-
dehyde in PBS followed by permeabilization with 0.2% Triton-X 100
(Sigma, USA) and processed with the mAbs and the supernatant of
SP2/0 cell. The presence of antigen–antibody reaction was visualized
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graphed using laser scanning confocal microscope (Olympus, Japan).
To further explore the diagnostic potential, the generated mAbs
were used in immunohistochemistry (IHC) assays on formalin-
ﬁxed, parafﬁn-embedded tissue sections obtained from SW/JL/07-
infected pigs. Ten 5-week-old pigs were obtained from a PRRSV-
seronegative farm. Four pigs were intramuscularly injected with
105 TCID50/2 mL of SW/JL/07, the other three pigs were inoculated
with the same dose of inactivated virus treated with 0.01%
formalin, and another three pigs were a negative control. Three
groups of pigs were kept separately. Venous blood was collected
every 5 days and sera were obtained for detection of Abs using the
commercial kit and the followed developed b-ELISA, respectively.
One of four pigs infected with live virus was exsanguinated on day
7 postinoculation when obvious symptoms (high fever, anorexia,
lethargy, and dyspnea) emerged and tissues were ﬁxed in 10%
formalin for 24 h and embedded in parafﬁn. Parafﬁn-embedded
tissues were used for IHC as described before (Gomez-Laguna
et al., 2009). In brief, duplicate sections of each tissue block were
stained with the mAb speciﬁc for the Nsp9 of PRRSV at 1:1000
dilution overnight at 4 1C. Sections were treated with biotinylated
secondary antibody (Vector Laboratories, USA) for 30 min at room
temperature followed by washing in PBST. Stained sections were
visualized using the NovaRED substrate kit (Vector Laboratories,
USA). Sections were counterstained with Harris’s hematoxylin,
dehydrated, and mounted with Eukitt (Sigma, USA). Sections were
visualized by light microscopy.
Development of a b-ELISA to differentiate Abs against live and
inactivated viruses
The ELISA system used in this study was a modiﬁcation of the
b-ELISA as previously described (Sorensen et al., 2005). The
b-ELISA for detection of Abs to PRRSV was performed using the
speciﬁc Nsp9 mAb. The optimal concentrations of mAb and
secondary Ab were determined by the square experiment. The
ELISA protocol was performed as follows: (i) 100 μL PRRSV
Nsp9 fusion protein was incubated at a predetermined dilution
(1.5 μg/mL) in coating buffer for 1 h at 37 1C; (ii) 5% BSA blocking
buffer for 1 h at 37 1C; (iii) test sera, positive and negative serum
controls were diluted 1:5 in blocking buffer (100 μL/well) and
incubated for 2 h at 37 1C; (iv) the mAb was added to the plates
(100 μL/well) at 1:10,000 dilution in PBST, and incubated for 1 h at
37 1C; (v) goat anti-mouse IgG-HRP (1:5000) in PBST was incu-
bated for 1 h at 37 1C; and (vi) 100 μL OPD substrate was allowed
to react for 20 min at room temperature before the addition of
50 μL of 2 M H2SO4 to stop the reaction. During the procedure,
wells were washed ﬁve times with washing buffer after each step.
OD readings were obtained at a wavelength of 490 nm. Results
were valid when the OD in negative control wells was over 0.8 OD
units. A cut-off of percent inhibition (PI) was used to distinguish
between negative and positive sera during the development of the
test parameters. PI¼100[(OD490 of test sample/ median OD490
negative control)100]. The cut-off value for the determination of
positive samples was set by the average OD ratio of 25 ﬁeld-
negative sera and 25 positive sera determined by b-ELISA. A
positive threshold for each assay was calculated using the
receiver-operator characteristic (ROC) analysis. The OD value of
negative control was the average OD of six negative controls.
To evaluate speciﬁcity of the b-ELISA, several antisera against
different viruses (CSFV, PPV, PRV, PCV, and JEV) related to swine
disease were evaluated as nonspeciﬁc serum samples. The sensi-
tivity of the assay was determined by comparing the PI values
obtained from a 1:5 dilution to 1:160 of 25 positive-control sera
identiﬁed by the commercial kit. The commercial kit was used as a
control. This b-ELISA was intended to detect the PRRSV Nsp9 Abs;therefore, if the Nsp9 Abs were detected, this would indicate the
presence of an actively replicating PRRSV. In order to detect the
b-ELISA titer, sera were diluted twofold. To further evaluate this
assay, precision within and between runs was also examined. The
same internal quality-control sera were used with the commercial
kit and the b-ELISA.
Comparison of commercial and b-ELISA tests
A total of 415 serum samples were collected at random from
animals with known immunization history of PRRS on six pig
farms (Table 1). All these ﬁled serum samples were tested for Abs
to PRRSV using the commercial kit and the b-ELISA. To conﬁrm the
assumption that inactivated vaccine does not induce Nsp9 speciﬁc
antibodies, 126 sera from herds vaccinated with an inactivated
vaccine were evaluated by both tests. 289 sera (except for
those against inactivated vaccines) were examined by both
tests to evaluate diagnostic sensitivity and speciﬁcity of b-ELISA.
The commercial kit was considered as the “standard” for this
comparison.
Statistical analysis
The ROC analysis was used to determine the cut-off value that
best differentiated negative and positive groups based on the value
obtained in the area under the curve. Standard deviations (SD),
percent coefﬁcient of variation (%CV) values were calculated using
the SPSS statistical software (version 13.0, SPSS Inc., Chicago,
Illinois, USA). Statistical signiﬁcance was deﬁned as a P-value of
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